Change on the Bachem Corporate Executive Committee

13-Dec-2019 - Bachem announced that Dr. Thomas Früh will be stepping down as CEO on health grounds effective January 1, 2020. Dr. Früh will continue to serve the company in a corporate services role. His successor as CEO will be current Chief Operations Officer (COO) and Corporate Executive Committee member ...

Thomas Meier to become new COO of Bachem Group

29-Oct-2018 - Bachem announced that Thomas Meier will succeed Dr. Alex Fässler as Chief Operations Officer of Bachem Group with effect from January 1, 2019. Dr. Alex Fässler will retire at the end of April 2019 yet will continue to serve the company in an advisory capacity. Thomas Meier was born in 1968 in ...

Bachem to expand in asian markets

Subsidiary in Tokyo founded

23-Jul-2018 - Bachem announces the establishment of Bachem Japan K.K., a subsidiary in Tokyo, Japan. This new local presence in Asia will strengthen project and customer support and drive further business growth in the Asian market."This is an exciting step for Bachem", comments Dr. Anne-Kathrin Stoller, Chief ...

Bachem expands its Corporate Executive Committee

27-Feb-2017 - Bachem announced that Dr. Alex Fässler has been appointed to its Corporate Executive Committee as a new member, effective April 1, 2017. Alex Fässler will have global responsibility for the Group’s production sites as Chief Operations Officer (COO). He will strengthen the Corporate Executive ...

Bachem renews supply contract with AstraZeneca

07-Feb-2017 - The Bachem Group announced the renewal of its supply agreement with AstraZeneca for the peptide active substance Goserelin. The extended partnership enhances the cooperation between both companies. Under the terms of the agreement, AstraZeneca will continue acquiring the peptide active substance ...

Bachem reinforced Collaboration with DOTTIKON ES

04-Oct-2016 - Bachem Group and DOTTIKON ES announce that they are extending their collaboration in the area of novel amino acids. The collaboration between the two Swiss companies covers the development, manufacturing, and distribution of enantiomerically pure amino acids, for example for peptide ...

Bachem: New sales record and sharp jump in profits

26-Aug-2016 - Bachem Group increased its sales in the first half of 2016 by 13.9% to a new record high of 113.4 million CHF (H1 2015: 99.6 million CHF). In local currency, sales grew 11.4%. Generics sales rose by approx. 9% to 53.9 million CHF. In the research ingredients business, catalog products and custom ...

Bachem: Record sales and creation of new jobs

Healthy order backlog, further sustainable growth expected

11-Mar-2016 - Bachem Group looks back on a successful fiscal year. Group sales reached a new record high of 208.6 million CHF (2014: 183.9 million CHF, +13.4% in CHF and +13.8% in local currency/LC). Excluding last year’s extraordinary gain of 2.0 million CHF on the divestment of the immunology product line, ...

Mymetics-Led Consortium Awarded €8.4 Million for Development of Thermo Stable and Cold-Chain Independent Vaccines

24-Apr-2015 - Mymetics Corporation announced that its subsidiary Mymetics BV in the Netherlands is leading a consortium that has been selected to receive project grants with a total value of €8.4 million. A total of €5.3 million is funded as part of Horizon 2020, the European Union research and innovation ...

Bachem continues its commitment to peptide chemistry at the University of Basel

04-Jul-2005 - As announced by Bachem Holding AG and the University of Basel, the company is renewing its financial sponsorship of the Bachem Professorship for Peptide Chemistry for a further three years. Accordingly, Bachem will provide a total of CHF 450,000 to the University of Basel up to mid-2008, in order ...